Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

November 30, 2015

Study Completion Date

December 31, 2015

Conditions
Neovascular Age Related Macular Degeneration
Interventions
DRUG

Lucentis (Treat and extend)

Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.

DRUG

Lucentis every 4 weeks

Lucentis 0.5mg administered intravitreally every four weeks for 12 months

DRUG

Lucentis every 12 weeks

Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months

Trial Locations (4)

85014

Retinal Consultants of Arizona, Phoenix

85210

Retinal Consultants of Arizona, Mesa

85296

Retinal Consultants of Arizona, Gilbert

85381

Retinal Consultants of Arizona, Peoria

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

Retinal Consultants of Arizona

OTHER

NCT01863199 - Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD) | Biotech Hunter | Biotech Hunter